Literature DB >> 19701224

Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide?

Brad H Rovin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19701224     DOI： 10.1038/nrneph.2009.130

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

3.  Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.

Authors:  C C Mok; C T Ho; Y P Siu; K W Chan; T H Kwan; C S Lau; R W Wong; T C Au
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

4.  Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages.

Authors:  G S Hill; M Delahousse; D Nochy; P Rémy; F Mignon; J P Méry; J Bariéty
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

5.  Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.

Authors:  Loke Meng Ong; Lai Seong Hooi; Teck Onn Lim; Bak Leong Goh; Ghazali Ahmad; Rozina Ghazalli; Sue Mei Teo; Hin Seng Wong; Si Yen Tan; Wan Shaariah; Chwee Choon Tan; Zaki Morad
Journal:  Nephrology (Carlton)       Date:  2005-10       Impact factor: 2.506

6.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Authors:  T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

7.  Severe lupus nephritis: racial differences in presentation and outcome.

Authors:  Stephen M Korbet; Melvin M Schwartz; Joni Evans; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

8.  Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.

Authors:  Weixin Hu; Zhihong Liu; Huiping Chen; Zhen Tang; Qinwen Wang; Keqin Shen; Lishi Li
Journal:  Chin Med J (Engl)       Date:  2002-05       Impact factor: 2.628

9.  The long-term outcome of 93 patients with proliferative lupus nephritis.

Authors:  Gabriella Moroni; Silvana Quaglini; Beniamina Gallelli; Giovanni Banfi; Piergiorgio Messa; Claudio Ponticelli
Journal:  Nephrol Dial Transplant       Date:  2007-05-17       Impact factor: 5.992

10.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121
  10 in total
  4 in total

Review 1.  Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Authors:  Lee A Hebert; Brad H Rovin
Journal:  Nephron Clin Pract       Date:  2010-08-03

Review 2.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

3.  Lupus nephritis: guidelines for lupus nephritis--more recommendations than data?

Authors:  Brad H Rovin
Journal:  Nat Rev Nephrol       Date:  2012-09-25       Impact factor: 28.314

4.  The kidney biopsy in lupus nephritis: is it still relevant?

Authors:  Brad H Rovin; Samir V Parikh; Anthony Alvarado
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.